The cobas® infinity POC tablet app builds on the original POC mobile app, but uses the larger tablet screen to enable additional functionality.
Early in 2016, Roche took its first step toward helping point-of-care coordinators (POCCs) manage important tasks while on the go with the launch of the cobas infinity point-of-care (POC) mobile app. Now, we are launching the next generation POC mobile app, one with broader reach and even more functionality.
Called cobas infinity POC tablet, this new app is a comprehensive tool that allows POCCs to do everything POC mobile could, and more. For extremely busy coordinators– who are often solely responsible for managing the entire POC service in a hospital, across a hospital campus, or even at several hospitals – this app frees them from their desk. They can now carry the tablet to meetings and call up instant reports; to the ward to show QC data directly to nurses; or to the education manager’s office to look at the current training situation.
Simplifying quality control (QC) to make work easier
With cobas infinity POC tablet, users can also easily monitor operator and device status, quickly identifying where problem-solving is needed. The QC review concept was designed to utilize the full potential of the tablet experience – you only need to click on a possible outlier result to see all result-related information, making it easy to pinpoint potential causes. Rules can also be configured so that the POC coordinator is alerted only to pre-defined issues, enabling them to use their time more efficiently.
Because the app has been designed with usability at its core, all data is presented in an intuitive way. This includes an interactive QC chart that can be used to quickly troubleshoot problems and record corrective actions, making daily work easier and allowing efficient compliance with accreditation requirements.
Designed by point-of-care coordinators, for point-of-care coordinators
The new tablet app is not merely the desktop cobas IT 1000 solution transferred to a tablet. Rather, it includes a re-engineered workflow designed to be as user-friendly as possible. During development, Roche undertook human design interaction studies, closely involving users. Each step of the workflow was evaluated for usability and adapted to reach the intuitive interface that our initial customers appreciated so much.
“Before POC Tablet I couldn’t be completely mobile. Now I have the freedom to move around the hospital and perform the tasks efficiently at every location. ” says Dianda Hemme a POCC from the Netherlands. “There is no need of paper any more to write things down like when replacing an instrument or when we have to train a user. It is so easy to use that I never again want to work without it.”
“The launch of the cobas infinity POC mobile tablet app is a continuation of the story we started last year with our initial POC mobile app,” says Youssef Khayali, Lifecycle Leader for Workflow and IT at Roche. “The tablet app now gives users additional features at their fingertips, and allows them to be on the move to work.”
cobas infinity POC mobile tablet is now available for iOS and Android devices and works in conjunction with the Roche cobas IT 1000 application. The app is the next component of the Roche “Personalized Lab Automation” portfolio, which was developed to provide quality, flexibility, efficiency and connectivity for every lab.
This first release is just the beginning of the journey for the tablet app – additional features will be developed to make the lives of POC coordinators even more efficient in the future.
About cobas IT 1000
The cobas IT 1000 solution allows for management of system configurations, test and material management, operator and point-of-care instrument management, as well as quality control and extensive reporting functions. It connects the full Roche POC portfolio including Accu-Chek® Inform II, CoaguChek® XS Plus and Pro, cobas h 232, cobas b 101, Urisys® 1100, cobas b 121, cobas b 123, cobas b 221.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.